Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3

BACKGROUND: Midostaurin combined with chemotherapy is currently used to treat newly diagnosed acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 (FLT3)-mutations. However, midostaurin acts as an antagonist to some chemotherapeutic agents in leukemia cell lines without FLT3 mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Hao, Weng, Xiang-qin, Sheng, Yan, Wu, Jing, Xi, Hui-min, Cai, Xun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270826/
https://www.ncbi.nlm.nih.gov/pubmed/35810308
http://dx.doi.org/10.1186/s12885-022-09828-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270826/
https://www.ncbi.nlm.nih.gov/pubmed/35810308
http://dx.doi.org/10.1186/s12885-022-09828-2

Ejemplares similares